Pharma

sponsor

Topics in Pharma

Conferences/Meetings

Drug/Product Approvals

Execs on the Move

Financial Reports

M&A/Partnerships

Marketing/Media/ROI

Medical Devices/Products

Physician/Patient Trends

Regulatory Issues

Research & Development

Become a Member Today!
Register

Most Viewed Abstracts

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

HIV protease inhibitors: recent clinical trials and recommendations on use
Expert Opinion in Pharmacotherapy, 06/19/09

Fernandez-Montero JV et al. - Due to their characteristics, PIs are, and will remain, a cornerstone component in most lines of antiretroviral therapy. The antiviral activity, tolerability and convenience of PIs have improved significantly in recent years. Differences between compounds within this class may favour their use in specific situations, such as the friendly metabolic profile of atazanavir in patients with cardiovascular disease or the high genetic barrier of darunavir or tipranavir in heavily pretreated individuals with HIV.

<< Previous
Maximizing the use of Project Bioshield contracting opportunities

Next >>
Smart planner: radically accelerating R and D to combat a...

Related Articles

Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Womens Interagency HIV Study
AIDS Patient Care and STDs, 11/19/09 Relevance Score: 95%

Effectiveness of Increasing Emergency Department Patients' Self-perceived Risk for Being Human Immunodeficiency Virus (HIV) Infected Through Audio Computer Self-interview–based Feedback About Reported HIV Risk Behaviors
Academic Emergency Medicine, 11/11/09 Relevance Score: 95%

HIV-Specific Health Care Utilization and Mortality among Tuberculosis/HIV Coinfected Persons
AIDS Patient Care and STDs, 10/06/09 Relevance Score: 95%

War and Peace between Microbes: HIV-1 Interactions with Coinfecting Viruses
Cell Host & Microbe, 11/23/09 Relevance Score: 94%

Mediators of HIV-related stigma and risk behavior in HIV infected young women
AIDS Care, 11/12/09 Relevance Score: 94%

Today in Drug Trials...keeping you current

Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09

Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09

Association of trial registration with the results and conclusions of published trials of new oncology drugs
Trials, 12/17/09

See all of Drug Trials

Article Search

Sponsor

Send this Summary to a Colleague